Esperion
Creative execution for today and life-saving innovation for tomorrow
339 employees · est. 2008 · Ann Arbor, United States
Pulmocide
Developing best-in-class inhaled medicines for targeted treatment of life-threatening respiratory diseases.
25 employees · est. 2013 · London, United Kingdom
Esperion is the older company (2008 vs 2013); Esperion is the larger of the two.
Side-by-Side Comparison
| Metric | Esperion | Pulmocide |
|---|---|---|
| Founded | ||
| Founded | 2008 older | 2013 |
| Headquarters | ||
| Headquarters | Ann Arbor, United States | London, United Kingdom |
| Employees | ||
| Employees | 339 larger | 25 |
| Industry | ||
| Industry | Biotechnology, Health Care, Pharmaceutical | Biotechnology, Health Care, Medical Devices |
| Funding Stage | ||
| Funding Stage | Post Ipo Equity | Series C |
| Total Funding | ||
| Total Funding | $852.55M | $194.90M |
| Funding Rounds | ||
| Funding Rounds | 8 | 5 |
| Services | ||
| Services | Not tracked yet | Development of Novel Inhaled Medicines, Clinical Development of Opelconazole, Treatment for Invasive Pulmonary Aspergillosis, Research on Aspergillus-related Conditions |
| Target Customers | ||
| Target Customers | Not tracked yet | Patients with Invasive Pulmonary Aspergillosis, Healthcare Providers, Medical Researchers, Pharmaceutical Companies |
| Taxonomy | ||
| Taxonomy | Pharmaceutical Company, Drug Discovery, Cardiovascular Diseases, Metabolic Diseases, High Cholesterol, Lipid Management, HDL Therapy, Small Molecule Drugs, LDL-C, Statins, Innovative Medicines, Entrepreneurial Team, Patient-centric Approach | Biopharmaceuticals, Respiratory Diseases, Inhaled Medicines, Fungal Infections, Pulmonary Aspergillosis, Lung Transplant, Drug Development, Inhaled Therapies, Infectious Diseases, Clinical Development, Pharmaceutical Industry |
| Website | ||
| Website | esperion.com | pulmocide.com |
About Esperion
Esperion is an innovative biotechnology and pharmaceutical startup that is singularly focused on disrupting high cholesterol to improve overall health. Founded in 1998 and headquartered in the United States, Esperion is committed to lipid management for everybody, striving to make its medicines acce...
About Pulmocide
Pulmocide, a biopharmaceutical company founded in 2013 and based in the United Kingdom, is pioneering the development of inhaled medicines for the targeted treatment of life-threatening respiratory diseases. Their core focus is on serious respiratory fungal infections, particularly pulmonary aspergi...
We will tell you when either one moves
BounceWatch watches Esperion and Pulmocide for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Esperion and Pulmocide — by email.
Frequently Asked Questions
Compare Esperion with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at Esperion on 12 Sep 2024, and Pulmocide on 11 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.